Journal of Neurology

, Volume 250, Supplement 3, pp iii44-iii46

First online:

Do patients with Parkinson’s disease benefit from embryonic dopamine cell transplantation?

  • Curt R. FreedAffiliated withDepartments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine Email author 
  • , Maureen A. LeeheyAffiliated withDepartments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine
  • , Michael ZawadaAffiliated withDepartments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine
  • , Kimberly BjugstadAffiliated withDepartments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine
  • , Laetitia ThompsonAffiliated withDepartments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine
  • , Robert E. BreezeAffiliated withDepartments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract.

Embryonic dopamine cell transplants survive in nearly all patients regardless of age and without immunosuppression. Transplants can improve Parkinson “off” symptoms up to the best effects of L-dopa observed preoperatively. They cannot improve the “best on” state. Transplants appear to survive indefinitely. In 10 to 15% of patients, transplants can reproduce the dyskinetic effects of L-dopa even after discontinuing all L-dopa. Neurotransplantation should be tried earlier in the clinical course of Parkinson’s to see if earlier intervention can prevent progression of the disease, particularly the dyskinetic responses seen after longterm L-dopa treatment.

Key words

putamen positron emission tomography (PET) fluorodopa embryonic stem cells double-blind neurosurgery